• Kobayashi M. Value-based Approach [18]Do you know about ISPOR as Society of Pharmacoeconomics? Cost-effectiveness evaluation learning at Society. Monthly Medical Information Express. 2018; 11:71-73. (in Japanese)

  • Kobayashi M. Value-based Approach [17] Health economics evaluation of Orphan Drug Orphan Drug is less evidence and also have different side from general medicine. Monthly Medical Information Express. 2018; 9:69-71. (in Japanese)

  • Kobayashi M. Value-based Approach [16] To be possible verifying hypothesis by utilizing the open data of NDB. How to play RWD. Monthly Medical Information Express. 2018; 8:73-75. (in Japanese)

  • Kobayashi M. Value-based Approach [15] Possibility and limit of RWD. We can play RWD. Monthly Medical Information Express. 2018; 7:73-75. (in Japanese)

  • Kobayashi M. Value-based Approach [14] Real Word Data The possibility to open by utilization of RWD. Monthly Medical Information Express. 2018; 6:75-77. (in Japanese)

  • Kobayashi M. Value-based Approach [13] Cost-effectiveness evaluation The result change in the main constitution. Whose money do you spend? Monthly Medical Information Express. 2018; 5:64-66. (in Japanese)

  • Kobayashi M. Value-based Approach [12] Evaluate unexpectedly every cost. Do you evaluate neatly burden of disease? Monthly Medical Information Express. 2018; 4:76-79. (in Japanese)

  • Kobayashi M. Value-based Approach [11] Be aware of invisible cost! Decline of labor productivity. Monthly Medical Information Express. 2018; 3:66-68. (in Japanese)

  • Kobayashi M. Learning from scratch, Introduction of “Cost-effectiveness evaluation”. Monthly Medical Information Express. 2018; 2:52-55. (in Japanese)

  • Kobayashi M. Value-based Approach [10] Value Evaluation of convenience and usability (5) A case of WTP research on Discrete Choice Experiment(DCE). Monthly Medical Information Express. 2018; 1:72-75. (in Japanese)


Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis

and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA